Paper41270342
AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.
Tankou J and 10 others. Gynecol Oncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer. Papers, record 41270342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41270342
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Endometrial Neoplasms | Major topic |
| Proto-Oncogene Proteins | Major topic |
| Trastuzumab | Major topic |
| Receptor Protein-Tyrosine Kinases | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Female | |
| Humans | |
| Axl Receptor Tyrosine Kinase | |
| Animals | |
| Mice | |
| Cell Line, Tumor | |
| Xenograft Model Antitumor Assays | |
| Erb-b2 Receptor Tyrosine Kinases | |
| Drug Synergism | |
| Cell Proliferation |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P50 CA265793 | NCI NIH HHS | United States | P50CA265793 | PubMed |
Source NIH RePORTER
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20642839 | Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. | J Mol Signal | 2010 | https://conductscience.org/library/papers/20642839 | PubMed |
| 2 | 24510676 | Preparation and use of reverse protein microarrays. | Curr Protoc Protein Sci | 2014 | https://conductscience.org/library/papers/24510676 | PubMed |
| 3 | 26153368 | The ImageJ ecosystem: An open platform for biomedical image analysis. | Mol Reprod Dev | 2015 | https://conductscience.org/library/papers/26153368 | PubMed |
| 4 | 37864955 | AXL - a new player in resistance to HER2 blockade. | Cancer Treat Rev | 2023 | https://conductscience.org/library/papers/37864955 | PubMed |
| 5 | 33049205 | Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer. | Cancer Cell | 2020 | https://conductscience.org/library/papers/33049205 | PubMed |
| 6 | 35546443 | Prognostic value of IGFBP2 in various cancers: a systematic review and meta-analysis. | Cancer Med | 2022 | https://conductscience.org/library/papers/35546443 | PubMed |
| 7 | 20861461 | Phosphorylation of threonine 154 in p40phox is an important physiological signal for activation of the neutrophil NADPH oxidase. | Blood | 2010 | https://conductscience.org/library/papers/20861461 | PubMed |
| 8 | 38726365 | Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. | iScience | 2024 | https://conductscience.org/library/papers/38726365 | PubMed |
| 9 | 30741844 | Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. | Int J Gynecol Pathol | 2020 | https://conductscience.org/library/papers/30741844 | PubMed |
| 10 | 25502142 | Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. | Nat Commun | 2014 | https://conductscience.org/library/papers/25502142 | PubMed |
| 11 | 38132919 | First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study. | Cancer Med | 2024 | https://conductscience.org/library/papers/38132919 | PubMed |
| 12 | 24398671 | Cigarette sidestream smoke induces histone H3 phosphorylation via JNK and PI3K/Akt pathways, leading to the expression of proto-oncogenes. | Carcinogenesis | 2014 | https://conductscience.org/library/papers/24398671 | PubMed |
| 13 | 35794161 | PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway. | Sci Rep | 2022 | https://conductscience.org/library/papers/35794161 | PubMed |
| 14 | 20417484 | Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. | Am J Obstet Gynecol | 2010 | https://conductscience.org/library/papers/20417484 | PubMed |
| 15 | 34407968 | Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34407968 | PubMed |
| 16 | 23816567 | Phosphorylation and degradation of S6K1 (p70S6K1) in response to persistent JNK1 Activation. | Biochim Biophys Acta | 2013 | https://conductscience.org/library/papers/23816567 | PubMed |
| 17 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 18 | 19840887 | Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. | Gynecol Oncol | 2010 | https://conductscience.org/library/papers/19840887 | PubMed |
| 19 | 36239552 | Alarming trends and disparities in high-risk endometrial cancer. | Curr Opin Obstet Gynecol | 2023 | https://conductscience.org/library/papers/36239552 | PubMed |
| 20 | 37773318 | ALK fusions in the pan-cancer setting: another tumor-agnostic target? | NPJ Precis Oncol | 2023 | https://conductscience.org/library/papers/37773318 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42835524 | AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer. | iScience | 2026 | https://conductscience.org/library/papers/42835524 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41270342
GET https://conductscience.org/api/papers/v1/41270342/references?page=2